4.33
-0.06 (-1.37%)
| Penutupan Terdahulu | 4.39 |
| Buka | 4.42 |
| Jumlah Dagangan | 41,463 |
| Purata Dagangan (3B) | 2,714,293 |
| Modal Pasaran | 386,877,280 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.85 |
| Harga / Buku (P/B) | 4.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Feb 2026 |
| EPS Cair (TTM) | -0.560 |
| Nisbah Semasa (MRQ) | 6.74 |
| Aliran Tunai Operasi (OCF TTM) | -29.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.69 M |
| Pulangan Atas Aset (ROA TTM) | -25.44% |
| Pulangan Atas Ekuiti (ROE TTM) | -40.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Anavex Life Sciences Corp. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 2.13 |
|
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.33% |
| % Dimiliki oleh Institusi | 37.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nwam Llc | 30 Sep 2025 | 874,283 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (D. Boral Capital, 454.27%) | Beli |
| Median | 22.00 (408.08%) | |
| Rendah | 20.00 (HC Wainwright & Co., 361.89%) | Beli |
| Purata | 22.00 (408.08%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.84 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 24.00 (454.27%) | Beli | 4.01 |
| 19 Dec 2025 | 24.00 (454.27%) | Beli | 3.67 | |
| HC Wainwright & Co. | 19 Dec 2025 | 20.00 (361.89%) | Beli | 3.67 |
| 28 Nov 2025 | 20.00 (361.89%) | Beli | 3.83 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |